Erratum: Acute and sustained effects of lucinactant versus poractant-α on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome (Pediatrics (2006) 117, (295-303) DOI: 10.1542/peds.2005-0378);Acute and sustained effects of lucinactant versus poractant-α on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome

Pediatrics

Volumn 117, Issue 2, 2006, Pages 295-303

  Gastiasoro Cuesta, Elena ^a   Alvarez Diaz, Francisco J ^a   Rey Santano, Carmen ^a   Arnaiz Renedo, Arantxa ^a   Loureiro Gonzalez, Begoña ^a   Valls i Soler, Adolf ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Natural surfactant; Premature lambs; Respiratory distress syndrome; Synthetic surfactant

Indexed keywords

LUCINACTANT; PORACTANT; BIOLOGICAL PRODUCT; FATTY ALCOHOL; PHOSPHATIDYLGLYCEROL; PHOSPHOLIPID; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PH; ARTERIAL PRESSURE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD GAS; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL ANIMAL; HEART RATE; LAMB; LUNG FUNCTION; LUNG GAS EXCHANGE; LUNG MECHANICS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; SURVIVAL; ANIMAL; BLOOD GAS ANALYSIS; BLOOD PRESSURE; DRUG COMBINATION; GESTATIONAL AGE; HUMAN; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; PATHOPHYSIOLOGY; SHEEP;

ANIMALS; ANIMALS, NEWBORN; BIOLOGICAL PRODUCTS; BLOOD GAS ANALYSIS; BLOOD PRESSURE; DRUG COMBINATIONS; FATTY ALCOHOLS; GESTATIONAL AGE; HEART RATE; HUMANS; INFANT, NEWBORN; PHOSPHATIDYLGLYCEROLS; PHOSPHOLIPIDS; PROTEINS; PULMONARY GAS EXCHANGE; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SHEEP;

EID: 33644872786     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-0929     Document Type: Erratum

References (56)

1. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child. 1959;97:517-523
2. Fujiwara T, Maeta H, Chida S, et al. Artificial surfactant therapy in hyaline-membrane disease. Lancet. 1980;1:55-59
3. Wilkinson A, Jenkins PA, Jeffrey JA. Two controlled trials of dry artificial surfactant: early effects and later outcome in babies with surfactant deficiency. Lancet. 1985;8:287-291
4. Halliday HL, Reid MM, Meban C, et al. Controlled trial of artificial surfactant to prevent respiratory distress syndrome. Lancet. 1984;3:476-478
5. Ten Center Study Group. Ten center trial of artificial surfactant (artificial lung expanding compound) in very premature babies. Br Med J. 1987;294:991-996
6. Phibbs RH, Ballard RA, Clements JA, et al. Initial clinical trial of Exosurf, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Pediatrics. 1991;88:1-9
7. Noack G, Berggren P, Curstedt T, et al. Severe neonatal respiratory distress syndrome treated with the isolated phospholipid fraction of natural surfactant. Acta Pediatr Scand. 1987;76:697-705
8. Horbar JD, Soll R, Sutherland JM, et al. A multicenter randomized, placebo-controlled trial of surfactant therapy for respiratory distress syndrome. N Engl J Med. 1989;320:959-965
9. Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics. 1988;82:683-691
10. Lang MJ, Hall RT, Reddy NS, Kurth CG, Merritt TA. A controlled trial of human surfactant replacement therapy for severe respiratory distress syndrome in very low birth weight infants. J Pediatr. 1990;116:295-300
11. Vilstrup C, Gommers D, Bos JAH, et al. Natural surfactant instilled in premature lambs increases lung volume and improves ventilation homogeneity within five minutes. Pediatr Res. 1992;32:595-599
12. Jobe AH, Ikegami M, Glatz T, et al. Duration and characteristics of treatment of premature lambs with natural surfactant. J Clin Invest. 1981;67:370-375
13. Alvarez FJ, Alfonso LF, Gastiasoro E, et al. The effects of multiple small doses of exogenous surfactant on experimental respiratory failure induced by lung lavage in rats. Acta Anaesthesiol Scand. 1995;39:970-974
14. Eijking EP, Gommers D, So KL, Vergeer M, Lachmann B. Surfactant treatment of respiratory failure induced by hydrochloric acid aspiration in rats. Anesthesiology. 1993;78:1145-1151
15. Cummings JJ, Holm BA, Hudak ML, et al. A controlled clinical comparison on four different surfactant preparations in surfactant deficient preterm lambs. Am Rev Respir Dis. 1992;145:999-1004
16. Ikegami M, Jobe AH, Jacobs HC, Jones SJ. Sequential treatments of premature lambs with an artificial surfactant and natural surfactant. J Clin Invest. 1981;68:491-496
17. Balaraman V, Sood SL, Finn KC, et al. Physiologic response and lung distribution of lavage versus bolus Exosurf in piglets with acute lung injury. Am J Respir Crit Care Med. 1996;153:1838-1843
18. Ikegami M, Jobe AH. Injury responses to different surfactants in ventilated premature lamb lungs. Pediatr Res. 2002;51:689-695
19. Morley C, Robertson B, Lachmann B, et al. Artificial surfactant and natural surfactant: comparative study of the effects on premature rabbit lungs. Arch Dis Child. 1980;55:758-765
20. Horbar JD, Wright LL, Soll RF, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr. 1993;123:757-766
21. Ainsworth SB, Beresford MW, Milligan DW, et al. Pumactant and poractant α for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet. 2000;355:1387-1392
22. Revak SD, Merritt TA, Degryse E, et al. Use of human surfactant low molecular weight apoprotein in the reconstitution of surfactant biologic activity. J Clin Invest. 1988;81:826-833
23. Curstedt T, Jornvall H, Robertson B, Bergman T, Berggren P. The hydrophobic low-molecular mass protein fractions of pulmonary surfactant: characterization and biophysical activity. Eur J Med Res. 1987;168:255-262
24. Tashiro K, Ohta K, Cui XG, et al. Effects of various forms of surfactant protein C on tidal volume in ventilated immature newborn rabbits. J Appl Physiol. 2003;94:1519-1526
25. Davis AJ, Jobe AH, Häfner D, Ikegami M. Lung function in premature lambs and rabbits treated with a recombinant SP-C surfactant. Am J Respir Crit Care Med. 1998;157:553-559
26. Kobayashi T, Tashiro K, Yamamoto K, et al. Effects of surfactant proteins SP-B and SP-C on dynamic and static mechanics of immature lungs. J Appl Physiol. 1997;83:1849-1856
27. Johansson J, Some M, Linderholm BM, et al. A synthetic surfactant based on poly-Leu SP-C analog and phospholipids: effects on tidal volumes and lung gas volumes in ventilated immature newborn rabbits. J Appl Physiol. 2003;95:2055-2063
28. Cochrane CG, Revak SD. Pulmonary surfactant protein B (SPB): structure-function relationships. Science. 1991;254:566-568
29. Cochrane CG, Revak SD. Surfactant lavage treatment in a model of respiratory distress syndrome. Chest. 1999;116:85S-87S
30. Cochrane CG, Revak SD, Merritt TA, et al. Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndrome. Pediatr Res. 1998;44:705-715
31. Revak SD, Merritt TA, Cochrane CG, et al. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res. 1996;39:715-724
32. Merritt TA, Kheiter A, Cochrane CG. Positive end-expiratory pressure during KL4 surfactant instillation enhances intrapulmonary distribution in a simian model of respiratory distress syndrome. Pediatr Res. 1995;38:211-217
33. Wiswell TE, Smith RM, Katz LB, et al. Bronchopulmonary segmental lavage with Surfaxin (KL4-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med. 1999;160:1188-1195
34. Cochrane CG, Revak SD, Merritt TA, et al. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153:404-410
35. Wiswell TE, Knight GR, Finer NN, et al. A multicenter, randomized, controlled trial comparing Surfaxin (lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics. 2002;109:1081-1087
36. Jobe AH, Ikegami M, Jacobs HC, Jones SJ. Surfactant pool sizes and severity of respiratory distress syndrome in prematurely delivered lambs. Am Rev Respir Dis. 1983;127:751-755
37. Björklund LJ, Ingimarsson J, Curstedt T, et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res. 1997;42:348-355
38. Notter RH, Egan EA, Kwong MS, Holm BA, Shapiro DL. Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: effects of dose, dispersion technique, and gestational age. Pediatr Res. 1985;19:569-577
39. Fisher JB, Mammel MC, Coleman JM, Bing DR, Boros SJ. Identifying lung overdistention during mechanical ventilation by using volume-pressure loops. Pediatr Pulmonol. 1988;5:10-14
40. Bhutani VK, Sivieri EM, Abbasi S, Shaffer TH. Evaluation of neonatal pulmonary mechanics and energetics: a two factor least mean square analysis. Pediatr Pulmonol. 1988;4:150-158
41. Sinha S, Lacaze-Masmonteil T, Valls-i-Soler A, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics. 2005;115:1030-1038
42. Moya F, Gadzinowski J, Bancalari E, et al. Multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics. 2005;115:1018-1029
43. Jobe A, Ikegami M: The prematurely delivered lamb as a model for studies of neonatal adaptation. In: Nathanielsz PW, ed. Animal Models in Fetal Medicine. Ithaca, NY: Perinatology Press; 1984;3:2-30
44. Wolfson MR, Shaffer TH. Liquid ventilation during early development: theory, physiologic processes and application. J Dev Physiol. 1990;13:1-12
45. Reller MD, Buffkin DC, Colasurdo MA, Rice MJ, McDonald RW. Ductal patency in neonates with respiratory distress syndrome: a randomized surfactant trial. Am J Dis Child. 2004;145:1017-1020
46. Collaborative European Multicenter Study Group. Factors influencing the clinical response to surfactant replacement therapy in babies with severe respiratory distress syndrome. Pediatrics. 1991;150:433-439
47. Robertson B, Curstedt T, Tubman R, et al. A 2-year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome. Eur J Pediatr. 1992;151:372-376
48. Rollins M, Jenkins J, Tubman R, Corkey C, Wilson D. Comparison of clinical responses to natural and synthetic surfactants. J Perinat Med. 1993;21:341-347
49. Johansson J, Curstedt T, Robertson B. The proteins of the surfactant system. Eur Respir J. 1994;7:372-379
50. Perez-Gil J, Keough KM. Interfacial properties of surfactant proteins. Biochim Biophys Acta. 1998;1408:203-217
51. Kobayashi T, Li WZ, Tashiro K, et al. Disparity between tidal and static volumes of immature lungs treated with reconstituted surfactants. J Appl Physiol. 1996;80:62-68
52. Häfner D, Germann PG, Hauschke D. Effects of rSP-C surfactant on oxygenation and histology in a rat-lung-lavage model of acute lung injury. Am J Respir Crit Care Med. 1998;158:270-278
53. Manalo E, Merritt TA, Kheiter A, Amirkhanian J, Cochrane CG. Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4. Pediatr Res. 1996;39:947-952
54. Herting E, Rauprich P, Stichtenoth G, et al. Resistance of different surfactant preparations to inactivation by meconium. Pediatr Res. 2001;50:44-49
55. Moses D, Holm BA, Spitale P, Liu M, Enhorning G. Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol. 1991;164:477-481
56. Schürch S, Amato M, Robertson B. Surface activity and structure of spread films in relation to surfactant concentration. Biol Neonate. 2002;81:37A